This is a working overview of Preclinical study, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-14. Anything still debated is marked as such rather than presented as settled.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or lower | For lyophilized powder; avoid repeated freeze-thaw. |
| Appearance | White to off-white powder | Common for lyophilized peptides. |
| Solubility | Soluble in water and aqueous buffers | Limited solubility in nonpolar solvents. |
| Typical analytical method | Reverse-phase HPLC and mass spectrometry | Used for purity and identity checks. |
| Typical purity specification | 95% or greater by HPLC area | Supplier values vary; not a biological potency measure. |
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
=== Retail editions === Half-Life 2 was simultaneously released through Steam, CD, and on DVD in several editions. Customers could order three versions: the" bronze" version includes only Half-Life 2 and Counter-Strike: Source, whereas the "silver" and "gold" editions also include Half-Life: Source and Day of Defeat: Source (ports of the original Half-Life and the Day of Defeat mod to the new engine). The "Gold Edition" additionally includes merchandise, such as a baseball cap, a strategy guide and a CD containing the soundtrack. The boxed retail copies come as standard and collector's editions. The collector's edition includes a T-shirt and sample of the Prima strategy guide. Both the disc and Steam versions require Steam to be installed and active for play to occur. None of the 2004 releases came with an instruction manual, though a reference card was included to guide people through installation and setup. In September 2005, Electronic Arts distributed a "Game of the Year Edition" of Half-Life 2, including Half-Life: Source.
Urocortin 2 (Ucn2) is an endogenous peptide in the corticotrophin-releasing factor (CRF) family. Urocortin II is a 38-amino acid peptide that is a member of the CRF family of peptides. Unlike Urocortin I, Urocortin II is highly selective for the CRF2 receptor and does not show affinity for the CRF binding protein.
==== Rodent research ==== A study on the fossil record of Asian rodents spanning the last 55 million years, providing evidence of impact of tectonic and climatic changes on ecomorphological diversity of Asian rodent assemblages throughouth their evolutionary history, is published by Peng & Hopkins (2026). Pfaff, Ruf & Le Maître (2026) determine the locomotory behavior of extinct members of Eusciurida on the basis of the study of middle and inner ear of extant and extinct rodents, interpreting early rodents and sciurids as fossorial, with adaptations to arboreal lifestyle evolving in later taxa. Review of research on systematics of fossil dormice from Mediterranean islands from the preceding years is published by Fox & Hennekam (2026). Wei et al. (2026) reconstruct the evolutionary history of marmots on the basis of paleontological and molecular data. Murchie et al. (2026) report evidence of preservation of ancient environmental DNA of diverse Quaternary organisms from eastern Beringia in the Pleistocene and Holocene ground squirrel coprolites from Yukon (Canada), including evidence of previously unrecognized genetic diversity of Arctic members of the genus Urocitellus. Li, Bi & Li (2026) present the first virtual endocasts of Paleogene ctenodactyloids Exmus mini and Bounomys ulantatalensis. The first fossil material of Hystrix subcristata from Taiwan is reported from the Pleistocene Chiting Formation by Halaçlar & Lin (2026). Buldrini et al. (2026) describe fossil material of Phugatherium sp.
Sources: en.wikipedia.org
All darmstadtium isotopes are extremely unstable and radioactive; in general, the heavier isotopes are more stable than the lighter. The most stable known darmstadtium isotope, 281Ds, is also the heaviest known darmstadtium isotope; it has a half-life of 14 seconds. The isotope 279Ds has a half-life of 0.18 seconds, while the unconfirmed 281mDs has a half-life of 0.9 seconds. The remaining isotopes and metastable states have half-lives between 1 microsecond and 70 milliseconds. Some unknown darmstadtium isotopes may have longer half-lives, however. Theoretical calculation in a quantum tunneling model reproduces the experimental alpha decay half-life data for the known darmstadtium isotopes. It also predicts that the undiscovered isotope 294Ds, which has a magic number of neutrons (184), would have an alpha decay half-life on the order of 311 years; exactly the same approach predicts a ~350-year alpha half-life for the non-magic 293Ds isotope, however.
Following ISIL's successful Anbar campaign and June 2014 offensive, the Badr Organization mobilized and won a series of battles against ISIL, including the Liberation of Jurf Al Sakhr and the Lifting of the Siege of Amirli. In early February 2015, the group, operating from its base at Camp Ashraf, fought in Diyala Governorate against ISIL. Over 100 militia were killed in the fighting, including 25 in Al Mansouryah. Badr's leader, Hadi al-Amiri, said his militiamen were committed to the safety of Sunnis, but deep mutual suspicions remained in the light of recent sectarian killings and the suspicion that some Sunni tribes were allied with IS. A leaked US diplomatic cable cited sources alleging that Hadi al-Amiri had personally ordered attacks on Sunnis.
Despite its small size, Singapore has a diversity of languages, religions, and cultures. Former prime ministers Lee Kuan Yew and Goh Chok Tong stated that Singapore does not fit the traditional description of a nation, calling it a society-in-transition, pointing out the fact that Singaporeans do not all speak the same language, share the same religion, or have the same customs. Singaporeans who speak English as their native language would likely lean toward Western culture (along with either Christian culture or secularism), while those who speak Chinese as their native language mostly lean toward Chinese culture, which has linkages with Chinese folk religion, Buddhism, Taoism and Confucianism. Malay-speaking Singaporeans mostly lean toward Malay culture, which itself is closely linked to Islamic culture. Tamil-speaking Singaporeans mostly lean toward Tamil culture, which itself is mostly linked to Hindu culture. Racial and religious harmony is regarded as a crucial part of Singapore's success, and played a part in building a Singaporean identity. When Singapore became independent from the United Kingdom in 1963, most Singaporean citizens were transient migrant labourers who had no intention of staying permanently. There was also a sizeable minority of middle-class, locally born people—known as Peranakans or Baba-Nyonya-descendants of 15th- and 16th-century Chinese immigrants. With the exception of the Peranakans who pledged their loyalties to Singapore, most of the labourers' loyalties lay with their respective homelands of Malaya, China and India.
A bifid or bifurcated uvula is a split or cleft uvula. Newborns with cleft palate often also have a split uvula. The bifid uvula results from incomplete fusion of the palatine shelves but it is considered only a slight form of clefting. Bifid uvulas have less muscle in them than a normal uvula, which may cause recurring problems with middle ear infections. While swallowing, the soft palate is pushed backwards, preventing food and drink from entering the nasal cavity. When the soft palate fails to close against the back of the throat during swallowing, food and liquid may pass into the nasal cavity. Splitting of the uvula occurs infrequently but is the most common form of mouth and nose area cleavage among newborns. Bifid uvula occurs in about 2% of the general population, although some populations may have a high incidence, such as Native Americans who have a 10% rate. Bifid uvula is a common symptom of the rare genetic syndrome Loeys–Dietz syndrome, which is associated with an increased risk of aortic aneurysm.
Sources: en.wikipedia.org
The lyophilized powder is commonly kept at -20 °C or lower, protected from moisture and light. Solutions may require colder storage and should avoid repeated freeze-thaw cycles. General peptide stability practices apply.
Reverse-phase HPLC can estimate purity, while mass spectrometry helps confirm molecular mass. These methods do not prove biological effects. Lot-specific certificates may provide additional data.
It is not an approved medicine in major jurisdictions. Depending on the country and marketing claims, it may be treated as a research chemical or unapproved substance. Import and sale rules vary.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.